Trend
DailyDowntrend (confirmed)
4 hourStrong Bullish
1 hourAscending Triangle
15 minStrong Bullish
5 minStrong Bullish
Daily trend turns up above $17.16
Key levels
Resistance$16.39
Resistance$14.86
Support$11.90
Support$10.57
Latest news & SEC filings
SEC FilingAdma Biologics, Inc. filed an insider trading report (Form 4)
NewsADMA Biologics CEO comments on ASCENIV's future
AnalystCantor Fitzgerald keeps Neutral rating on ADMA Biologics, lifts price target
All ADMA news →ADMA Biologics is a commercial biopharmaceutical company that develops, produces, and sells plasma-derived treatments for people with weakened immune systems and those at risk of certain infections. Its marketed medicines include ASCENIV and BIVIGAM, both intravenous immune globulins for primary humoral immunodeficiency, and Nabi-HB for acute Hepatitis B exposure. The company operates a plant in Boca Raton, Florida, where it separates and refines blood plasma, along with a group of source plasma collection centers across the United States. Its customers include physician specialists, third-party plasma purchasers, and contract manufacturing clients.
Based on the company's 10-K filed Feb 25, 2026.
Nasdaq · Healthcare
SEPT Low Target
$17.00
SEPT Mid Target
$17.50
SEPT High Target
$18.00
Analyst Consensus
$17.50
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ADMA.
Start Free Trial →Valuation Verdict
FAIR
Methods Used
P/E Forward, P/B, Analyst Consensus
Fair Value
$14.73
75
Moat Score
WIDE
5/9
Piotroski Score
13.3
Altman Z-Score
Insider Signal
BUYING
5 buys / 1 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Grossman Adam S | director officer | Buy | 105,000 | $567K | Nov 5, 2026 |
| Grossman Adam S | director officer | Sale | 105,000 | $1.3M | Nov 5, 2026 |
| Grossman Adam S | director officer | Sale | 42,000 | $504K | Nov 5, 2026 |
| Grossman Jerrold B | director | Buy | 6,400 | $51K | May 27, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
19.6%
3yr Revenue CAGR
49.0%
EPS Growth YoY
-25.93%
FCF Growth YoY
-74.8%
Revenue Trend
STRONG
SEPT Investing tracks real-time dark pool institutional trades for ADMA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 19:31:14 | $13.37 | 9,800 | $$131K | BUY |
| 19:25:33 | $13.38 | 24,822 | $$332K | MIDPOINT |
| 19:23:49 | $13.41 | 1,195 | $$16K | BUY |
| 19:20:41 | $13.43 | 3,000 | $$40K | SELL |
| 19:12:14 | $13.42 | 3,000 | $$40K | SELL |
5 dark pool trades shown · $$560K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT Investing provides real-time options flow tracking for ADMA, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $11 | Nov 20 | 8 | $$217 | 1 | SWEEP |
| CALL | $15 | Jan 21 | 435 | $$229 | 1 | SWEEP |
| CALL | $11 | Nov 20 | 8 | $$21.9K | 100 | BLOCK |
| CALL | $15 | Dec 18 | 36 | $$20 | 1 | SWEEP |
| PUT | $13 | Jan 15 | 64 | $$425 | 5 | SWEEP |
5 options trades shown · 80% calls
Unusual activity, GEX levels, max pain, and dealer positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for ADMA BIOLOGICS, INC. (ADMA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ADMA BIOLOGICS, INC. (ADMA) is at $13.38, up 1.40% (+$0.19) at the Nov 12, 2026 close.
Latest ADMA news — Nov 5, 2026: Adma Biologics, Inc. filed an insider trading report (Form 4) · Nov 5, 2026: ADMA Biologics CEO comments on ASCENIV's future
The average analyst price target for ADMA is $17.50, ranging from $17 to $18, based on 2 analysts. Latest: Mizuho maintains on Jul 15, 2026.
Analyst ratings for ADMA: 0 Buy, 4 Hold, 1 Sell — consensus Hold.
ADMA last reported on Aug 5, 2026: EPS $0.16 vs $0.16 expected — a miss of 2.0%.
ADMA trades at a P/E of 15.9 vs a Healthcare average of 17.7.
ADMA does not currently pay a dividend.
ADMA BIOLOGICS, INC. reported $197M of debt and $136M of cash (Jun 30, 2026).
Support: $11.90, $10.57, $9.62. Resistance: $14.86, $16.39, $17.16.
Insider activity: BUYING, 5 buys and 1 sells in the last 90 days.
Nov 5, 2026: Adma Biologics, Inc. filed an insider trading report (Form 4) · Nov 5, 2026: ADMA Biologics CEO comments on ASCENIV's future · Nov 5, 2026: Cantor Fitzgerald keeps Neutral rating on ADMA Biologics, lifts price target